Case of a Сombination of Lupus Erythematosus, Antiphospholipid Syndrome and Myocardial Infarction
https://doi.org/10.18087/cardio.2019.12.n610
Abstract
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease of unknown etiology characterized by a wide range of clinical manifestations with damage to various organs and systems of the body. There are bad prognostic factors for SLE: damage to the heart, kidney, central nervous system, the development of hematological crises and secondary antiphospholipid syndrome. A number of authors consider systemic lupus erythematosus a “new” risk factor for atherosclerosis. The overall risk of myocardial infarction (MI) in patients with SLE is 10 times higher than in the general population. The article presents clinical case report of the development of myocardial infarction in a woman with SLE, receiving therapy for secondary antiphospholipid syndrome.
About the Authors
N. A. Kosheleva
Saratov State Medical University named after V. I. Razumovsky
Russian Federation
Russian Federation
Kosheleva Natalia A. – MD, professor
Saratov
N. M. Nikitina
Saratov State Medical University named after V. I. Razumovsky
Russian Federation
Saratov
Russian Federation
Saratov
E. U. Andreeva
Saratov State Medical University named after V. I. Razumovsky
Russian Federation
Saratov
Russian Federation
Saratov
References
1. Nikitina N.M., Afanasyev I.A., Rebrov A.P. Comorbidity in patients with rheumatoid arthritis. Rheumatology Science and Practice. 2015;53(2):149–54. DOI: 10.14412/1995-4484-2015-149–154
2. Moltó A, Nikiphorou E. Comorbidities in Spondyloarthritis. Frontiers in Medicine. 2018;5:62. DOI: 10.3389/fmed.2018.00062
3. Popkova T.V., Alekberova Z.S., Aleksandrova E.N., Bulgakova O.V., Nasonov E.L. Risk factors of cardiovascular disorders and atherosclerosis in systemic lupus red. Scientific and practical rheumatology. 2004;4:10–4.
4. Di Minno M, Iervolino S, Lupoli R, Russolillo A, Coppola A, Peluso R et al. Cardiovascular Risk in Rheumatic Patients: The Link between Inflammation and Atherothrombosis. Seminars in Thrombosis and Hemostasis. 2012;38(05):497–505. DOI: 10.1055/s-0032-1306433
5. Peters MJL, Symmons DPM, McCarey D, Dijkmans BAC, Nicola P, Kvien TK et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Annals of the Rheumatic Diseases. 2010;69(2):325–31. DOI: 10.1136/ard.2009.113696
6. Alekberova Z.S., Aleksandrova E.N., Alekseeva L.I. Russian clinical recommendations. Rheumatology. ed. by Nasonov E.L. -M.: GEOTAR-Media; 2017. - 456 p. ISBN 978-5-9704-4261-6
7. Nasonov E.L., Nasonova V.A. Rheumatology: National Leadership. -M.: GEOTAR-Media; 2008. - 714 p. ISBN 978-5-9704-0672-4
8. Stojan G, Petri M. Atherosclerosis in Systemic Lupus Erythematosus: Journal of Cardiovascular Pharmacology. 2013;62(3):255–62. DOI: 10.1097/FJC.0b013e31829dd857
9. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis and Rheumatism. 2001;44(10):2331–7. DOI: 10.1002/1529-0131(200110)44:10<2331::aid-art395>3.0.co;2-i
10. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jansen-McWilliams L et al. Age-specific Incidence Rates of Myocardial Infarction and Angina in Women with Systemic Lupus Erythematosus: Comparison with the Framingham Study. American Journal of Epidemiology. 1997;145(5):408–15. DOI: 10.1093/oxfordjournals.aje.a009122
11. Karpenko Yu.Yu., Sudakov A.V. Pathology of internals at a late stage of a system red volchanka. Systems analysis and management in biomedical systems. 2011;10(4):936–41.
12. Ilyina A.E., Klyukvina N.G., Aleksandrova E.N., Popkova T.V., Novikov A.A., Novikova D.S. et al. Soluble receptors of TNFalpha: association with atherosclerotic vascular affection in systemic lupus erythematosus in males. Therapeutic Archive. 2006;78(6):20–4.
13. Rajagopalan S, Somers EC, Brook RD, Kehrer C, Pfenninger D, Lewis E et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood. 2004;103(10):3677–83. DOI: 10.1182/blood-2003-09-3198
14. Nasonov E.L. Antiphospholipid syndrome. -M.: Litterra; 2004. - 440 p. ISBN 978-5-98216-010-2
15. Bessant R, Duncan R, Ambler G, Swanton J, Isenberg DA, Gordon C et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case–control study. Arthritis & Rheumatism. 2006;55(6):892–9. DOI: 10.1002/art.22343
16. Reshetnyak Т.М., Alekberova Z.S., Alexandrova E.N. The clinicaland-immunological aspects of anti-phospholipid syndrome. Annals of the Russian academy of medical sciences. 2003;7:31–4.
17. Margarita A LL. Atherosclerosis in Primary Antiphospholipid Syndrome: Summary of Clinical and Pathogenic Evidence. Journal of Clinical & Experimental Cardiology. 2014;5(2):293. DOI: 10.4172/2155-9880.1000293
18. Nasonov E.L. Antiphospholipid syndrome: diagnosis, clinic, treatment. Russian Medical Journal. 1998;6(18):4–6.
19. Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK. Antibodies Against Cardiolipin and Oxidatively Modified LDL in 50-Year-Old Men Predict Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17(11):3159–63. DOI: 10.1161/01.ATV.17.11.3159
20. Vaarala O, Mänttäri M, Manninen V, Tenkanen L, Puurunen M, Aho K et al. Anti-Cardiolipin Antibodies and Risk of Myocardial Infarction in a Prospective Cohort of Middle-Aged Men. Circulation. 1995;91(1):23–7. DOI: 10.1161/01.CIR.91.1.23
21. Roman MJ, Shanker B-A, Davis A, Lockshin MD, Sammaritano L, Simantov R et al. Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus. New England Journal of Medicine. 2003;349(25):2399–406. DOI: 10.1056/NEJMoa035471
22. Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis and Rheumatism. 1999;42(1):51–60. DOI: 10.1002/1529-0131(199901)42:1<51::AID-ANR7>3.0.CO;2-D
23. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S et al. Premature Coronary-Artery Atherosclerosis in Systemic Lupus Erythematosus. New England Journal of Medicine. 2003;349(25):2407–15. DOI: 10.1056/NEJMoa035611
24. Toloza SMA, Uribe AG, McGwin G, Alarcón GS, Fessler BJ, Bastian HM et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIII. Baseline predictors of vascular events: Predictors of Vascular Events in SLE. Arthritis & Rheumatism. 2004;50(12):3947–57. DOI: 10.1002/art.20622
25. McMahon M, Grossman J, Skaggs B, FitzGerald J, Sahakian L, Ragavendra N et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis & Rheumatism. 2009;60(8):2428–37. DOI: 10.1002/art.24677
26. Pengo V, Bison E, Ruffatti A, Iliceto S. Antibodies to oxidized LDL/β2-glycoprotein I in antiphospholipid syndrome patients with venous and arterial thromboembolism. Thrombosis Research. 2008;122(4):556–9. DOI: 10.1016/j.thromres.2007.12.028
27. Gualtierotti R, Biggioggero M, Meroni PL. Cutting-Edge Issues in Coronary Disease and the Primary Antiphospholipid Syndrome. Clinical Reviews in Allergy & Immunology. 2013;44(1):51–6. DOI: 10.1007/s12016-011-8268-9
28. Meroni PL, Raschi E, Testoni C, Borghi MO. Endothelial cell activation by antiphospholipid antibodies. Clinical Immunology. 2004;112(2):169–74. DOI: 10.1016/j.clim.2004.02.015
29. Rho YH, Chung CP, Oeser A, Solus J, Raggi P, Gebretsadik T et al. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. The Journal of Rheumatology. 2008;35(9):1789–94. PMID: 18634156
30. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nature Immunology. 2011;12(3):204–12. DOI: 10.1038/ni.2001
Review
For citations:
Kosheleva N.A., Nikitina N.M., Andreeva E.U. Case of a Сombination of Lupus Erythematosus, Antiphospholipid Syndrome and Myocardial Infarction. Kardiologiia. 2019;59(12):92-96. (In Russ.) https://doi.org/10.18087/cardio.2019.12.n610
Views:
2571
Email this article 
Post a Comment 
